# Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC

> **NCT02497118** · PHASE4 · COMPLETED · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Endostatin
- **DRUG:** Vinorelbine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02497118
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2015-04
- **Final completion:** 2015-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497118, "Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02497118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*